UNSPSC 51271613: Lidocaine

This classification denotes a cation channel blocker and anesthetic agent with the molecular formula C14H22N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 98PI200987, chemically known as 2-diethylamino-n-(2,6-dimethylphenyl)-ethanamide but generally known as lidocaine, which bears US NIH Compound Identifier 3676. European Medicines Agency schedules Lidocaine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08507MIG.

UNSPSC 51271613 Lidocaine, a Commodity code, covers lidocaine products supplied through state and local pharmaceutical procurement frameworks. State and local governments procure lidocaine as part of broader generic pharmaceutical and over-the-counter product contracts distributed across state agencies, county health systems, municipal facilities, and other public health entities. Recent solicitations show lidocaine and similar injectable anesthetics being sourced through multi-state cooperative purchasing agreements that consolidate purchasing across multiple jurisdictions and requiring vendors to supply products through designated wholesale distribution partners (AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co., LLC) with full National Drug Codes, SKUs, UPCs, strength, dosage form, and packaging specifications. Vendors must hold current Good Manufacturing Practices (cGMP) certification and Drug Supply Chain Security Act (DSCSA) compliance, maintain contractual relationships with at least two of three authorized wholesalers with chargeback systems in place, and carry comprehensive insurance including $5 million commercial general liability, $2 million network security and privacy liability, and $2 million professional liability coverage. Pricing is weighted heavily (75 percent of evaluation) with additional scoring on fixed pricing (10 percent), administrative fee format compliance (5 percent), EDI capability (5 percent), and willingness to accept a 3 percent administrative fee (5 percent).

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP (S1070000015802) on January 20, 2026, with a due date of March 26, 2026, for generic multi-source pharmaceuticals and OTC products to be distributed across participating state and local facilities including Oregon. The contract term is two years for new responders with optional extensions at MMCAP's discretion, with incumbent responders' amendments aligning with existing agreement expiration dates through June 30, 2028. All products must be available by May 15, 2026, with awarded vendor agreements effective July 1, 2026. Vendors may submit pricing in flat price, net price formats (NF30, NF60, NF90), or WAC-minus structures, and performance penalties range from $200 to $1,500 per violation for late reporting, missed onboarding timelines, or improper class-of-trade denials. Submissions are made through the ePro procurement system using Google Chrome with pricing and product data in Excel/CSV format.